These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 37077919)

  • 1. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
    Yang Q; Zhu W; Gong H
    Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
    Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
    Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anoikis-related subtype and prognosis analyses based on bioinformatics, and an expression verification of ANGPTL4 based on experiments of lung adenocarcinoma.
    Shen X; Xie J; Liu S; Cai Y; Yuan S; Uehara Y; Zhu D; Zheng M
    J Thorac Dis; 2024 Aug; 16(8):5361-5378. PubMed ID: 39268091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
    BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
    Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
    Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
    Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
    Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
    Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt signaling pathway-derived score for predicting therapeutic resistance and tumor microenvironment in lung adenocarcinoma.
    Zhou HM; Zhao LM
    Front Pharmacol; 2022; 13():1091018. PubMed ID: 36703749
    [No Abstract]   [Full Text] [Related]  

  • 14. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
    Wang Y; Zhang G; Wang R
    Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
    Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
    Front Immunol; 2022; 13():960738. PubMed ID: 36032135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes.
    Wang Z; Zhang J; Shi S; Ma H; Wang D; Zuo C; Zhang Q; Lian C
    Sci Rep; 2023 Sep; 13(1):15198. PubMed ID: 37709932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
    Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
    Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
    Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
    Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8
    Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
    Front Immunol; 2022; 13():806877. PubMed ID: 35273597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors analysis and survival prediction model establishment of patients with lung adenocarcinoma based on different pyroptosis-related gene subtypes.
    Wen Z; Pei B; Dai L; Lu P; Li X; Zhang C; Ge S
    Eur J Med Res; 2023 Dec; 28(1):601. PubMed ID: 38111060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.